The CMT Research Foundation has one single focus: deliver treatments and cures for CMT.  Led by two experts in Charcot-Marie-Tooth (CMT) who have over 20 years of collective experience working with CMT researchers, the CMTRF supports the most promising and effective research aimed at drug delivery. By developing strategic partnerships with researchers, pharmaceutical and biotechnology professionals, as well as a national network of CMT patients, the CMT Research Foundation is instrumental in achieving successful outcomes in CMT research for treatment and cure delivery.

CMT is a progressive genetic nerve disease and can lead to severe disability or even death. CMT has over 90 known genetic causes and can be passed down in multiple generations. Onset can be at birth or later in life and is characterized by loss of muscles and sensation in the feet, hands, legs and arms. Nearly three million people of every age, race and ethnicity are living with CMT. Currently there is no cure for CMT; and there are not any effective treatments. 

CMT is a genetic disease with a high unmet need, giving pharmaceutical companies incentives to deliver clinical trials and eventually, treatments and cures for CMT. With your help, the CMT Research Foundation will not stop until cures for all types of CMT have been delivered.

Biotechnology

Life Sciences

Pharmaceutical

Research

Therapeutics

CMT Research Foundation

Cleary Simpson

Susan Ruediger

George Simpson

Anna Combes

Erich M. Fasnacht

Leadership Team

Communications Team

Teams at CMT Research Foundation

Leadership Team

Communications Team